Regeneron has been busy, with two health tech deals announced this week: One is about genetic data and one about AI. Both of ...

Company Leverages More Than Twenty Years of Drug Response Data Derived from Massive Biobank of Live Cell Tumor ...

Using Gibson SOLA at scale is intended to contribute to an agile and efficient approach to biologics discovery. The Gibson SOLA platform has been shown to enable fully-enzymatic, overnight, on-site ...

Predictive Oncology Inc. (NASDAQ: POAI) moves to leverage its vast biobank of more than 150,000 heterogenous live cell tumor samples and drug response data ...

Not unlike Regeneron’s acquisition of 23andMe, Predictive Oncology’s AI-driven breakthroughs reflect ... early drug discovery and enable drug development for the benefit of cancer patients ...

Pittsburgh, Pennsylvania Saturday, May 24, 2025, 15:00 Hrs [IST] ...

Modern healthcare is increasingly reliant on genetic testing. Its significance is at an all-time high due to its applications ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) announced Monday that it has secured the winning bid in the bankruptcy auction ...

Sanofi (ENXTPA:SAN) recently entered into a multi-year partnership with Viz.ai and Regeneron to develop an AI-powered solution for COPD management, reflecting its focus on innovation. Over the last ...

Shares of OraSure Technologies Inc (NASDAQ:OSUR) climbed 7.4% today after news that Regeneron Pharmaceuticals (NASDAQ:REGN) has been named the successful bidder in the bankruptcy auction for 23andMe, ...

The planned purchase will allow Regeneron to integrate 23andMe’s extensive genetic data into its research efforts, potentially leading to new medical advancements. Regeneron has stated its commitment ...

Drugmaker Regeneron Pharmaceuticals, Inc. (REGN) said on Monday that it will acquire the assets of bankrupt biotechnology ...